European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Issued: London, UK
For media and investors only
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
In Europe, RSV leads to over 270,000 hospitalisations and approximately...
Zur Pressemeldung auf www.gsk.com